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Patterns and functional implications of rare
germline variants across 12 cancer types
Charles Lu1,*, Mingchao Xie1,2,3,*, Michael C. Wendl1,3,4,*, Jiayin Wang1,2,*,w, Michael D. McLellan1,*,
Mark D.M. Leiserson5,6,*, Kuan-lin Huang1,2, Matthew A. Wyczalkowski1,2, Reyka Jayasinghe1,2,
Tapahsama Banerjee7, Jie Ning1,2, Piyush Tripathi2, Qunyuan Zhang1, Beifang Niu1, Kai Ye1,3, Heather K. Schmidt1,
Robert S. Fulton1,3, Joshua F. McMichael1, Prag Batra1, Cyriac Kandoth1, Maheetha Bharadwaj1, Daniel C. Koboldt1,
Christopher A. Miller1, Krishna L. Kanchi1, James M. Eldred1, David E. Larson1,3, John S. Welch2,8,
Ming You9, Bradley A. Ozenberger1,2, Ramaswamy Govindan2,8, Matthew J. Walter2,8, Matthew J. Ellis2,8,
Elaine R. Mardis1,2,3,8, Timothy A. Graubert2,8, John F. Dipersio2,8, Timothy J. Ley1,2,3,8, Richard K. Wilson1,2,3,8,
Paul J. Goodfellow7, Benjamin J. Raphael5,6, Feng Chen2,8, Kimberly J. Johnson10, Jeffrey D. Parvin7,11
& Li Ding1,2,3,8
Large-scale cancer sequencing data enable discovery of rare germline cancer susceptibility
variants. Here we systematically analyse 4,034 cases from The Cancer Genome Atlas cancer
cases representing 12 cancer types. We ﬁnd that the frequency of rare germline truncations in
114 cancer-susceptibility-associated genes varies widely, from 4% (acute myeloid leukaemia
(AML)) to 19% (ovarian cancer), with a notably high frequency of 11% in stomach cancer.
Burden testing identiﬁes 13 cancer genes with signiﬁcant enrichment of rare truncations,
some associated with speciﬁc cancers (for example, RAD51C, PALB2 and MSH6 in AML,
stomach and endometrial cancers, respectively). Signiﬁcant, tumour-speciﬁc loss of hetero-
zygosity occurs in nine genes (ATM, BAP1, BRCA1/2, BRIP1, FANCM, PALB2 and RAD51C/D).
Moreover, our homology-directed repair assay of 68 BRCA1 rare missense variants supports
the utility of allelic enrichment analysis for characterizing variants of unknown signiﬁcance.
The scale of this analysis and the somatic-germline integration enable the detection of rare
variants that may affect individual susceptibility to tumour development,
a critical step toward precision medicine.
DOI: 10.1038/ncomms10086 OPEN
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A
t least 3% of all cancer cases are thought to have a strong
hereditary component, with large variation being found
across cancer types1. For example, it was recently
estimated that up to 20–25% of ovarian cancers are due to a
germline loss-of-function variant in one of several genes that
confer moderate-to-high risk2,3, while other cancer types (for
example, lung) have strong environmental components with little
evidence of genetic predisposition4. The absence of heritability in
some cancers may be due to low or medium penetrance alleles5.
Genome-wide association studies (GWAS) have been
instrumental in identifying hundreds of common low-effect risk
alleles across multiple cancer types6. The availability of large-scale
normal and tumour-sequencing data from cancer cases now
allows for discovery of rare variants inﬂuencing cancer
susceptibility through analysis of both germline and somatic
sequencing data.
Tumorigenesis is a complex process that often involves close
interactions between germline and somatic variants. Their
cooperation is best exempliﬁed by the ‘two-hit hypothesis’7,
in which a tumour suppressor gene is inactivated by the
combination of an initial germline mutation of one allele,
followed by the somatic inactivation of the other. Loss of
heterozygosity (LOH), whereby the wild-type (WT) allele for a
two-hit tumour suppressor is eliminated, has been implicated in
many cancers8,9. Advancing our understanding of cooperative
germline-somatic dynamics and their implications for
tumorigenesis requires large cohort studies using sequencing
data from both germline and somatic tissues, as well as new tools
to reliably detect allelic loss.
We have previously reported that whole exome sequencing
data can be successfully employed to identify both known high
penetrance cancer genes in ovarian cancer, as well as new
candidate predisposition alleles for downstream functional
characterization3. Here we extend this work to 12 cancer types
with the goal of describing the landscape of germline variants
(truncation and missense) and analysing the effect of germline
variants on somatic mutations using 44,000 cancer cases.
Our analysis shows a diverse set of genes potentially
contributing to predisposition with variable frequencies and
levels. Stomach cancer has a relatively high rate of rare germline
truncations, in large part due to frequent PALB2 and ATM
mutations. Genes and local hotspots of signiﬁcant allelic
enrichment within functional domains were discovered through
integrating germline and somatic data. Germline and somatic
integration sheds insights on genes inﬂuencing somatic mutation
frequencies and genes/pathways involved in the entire life history
of individual tumours. Experimental validation of 68 BRCA1
variants, with 62 having previously unknown functional
signiﬁcance or not reported by the NHGRI Breast Cancer
Information Core (BIC) database, identiﬁed 9 with complete or
partial loss of homology-directed repair (HDR) function, further
supporting LOH analysis results. Such discovery of new cancer
susceptibility genes and functional characterization of variant
alleles will be an important step towards generating an actionable
catalogue for personalized treatment of cancer.
Results
Cancer types and sample characteristics. We searched for
candidate germline cancer predisposition variants in the exome
sequence data from 4,034 cancer patients across 12 diverse cancer
types: breast adenocarcinoma (BRCA), glioblastoma multiforme
(GBM), head and neck squamous cell carcinoma (HNSC), kidney
renal clear cell carcinoma (KIRC), acute myeloid leukaemia
(AML), low grade glioma (LGG), lung adenocarcinoma (LUAD),
lung squamous cell carcinoma (LUSC), ovarian carcinoma (OV),
prostate adenocarcinoma (PRAD), stomach adenocarcinoma
(STAD) and uterine corpus endometrial carcinoma (UCEC).
The numbers of cases from each tumour type ranged from 178
(PRAD) to 770 (BRCA) and are listed in Table 1. Of the 3,548
TCGA cases with available ethnicity information, 88.1% were
Caucasian (n¼ 3,125), 6.3% were African American (n¼ 225),
5.2% were Asian (n¼ 183) and 0.4% (n¼ 15) were American
Indian/Alaska Native. Patients (n¼ 3,827) were diagnosed
between 10 and 90 years (mean 59.9±13.2 years) with LUSC and



































BRCA Discovery 770 770 58.2±13.2 1.04 98.96 1 50 53 578 88 682 88 0
Validation 217 200 59.5±12.8 0.5 99.5 0 6 64 124 6 189 11 0
GBM Discovery 267 267 59.6±14.0 60.9 39.1 0 4 21 237 5 89 176 1
Validation 124 118 61.0±12.4 62.71 37.29 0 3 3 107 5 36 81 1
HNSC Discovery 291 261 60.9±12.4 71.26 28.74 1 4 26 223 7 153 108 0
Validation 222 192 60.3±11.3 73.44 26.56 0 5 9 174 4 155 37 0
KIRC Discovery 452 452 60.7±12.1 64.82 35.18 0 7 20 419 6 306 146 0
Validation 42 39 58.5±12.2 76.92 23.08 0 1 7 31 0 27 12 0
Discovery 200 200 55.0±16.1 54.50 45.50 0 2 15 181 2 67 133 0
LGG Discovery 223 220 43.0±13.5 57.73 42.27 0 0 9 209 2 169 51 0
Validation 240 181 43.5±13.5 51.93 48.07 1 4 6 167 3 167 14 0
LUAD Discovery 462 387 65.2±9.9 46.25 53.75 1 5 23 297 61 294 93 0
Validation 94 76 66.7±9.5 46.05 53.95 0 1 3 67 5 51 25 0
LUSC Discovery 193 139 67.7±9.3 74.82 25.18 0 0 4 113 22 93 46 0
Validation 183 139 66.1±8.4 78.42 21.58 0 6 3 79 51 103 36 0
OV Discovery 429 429 59.4±11.8 0 100 2 15 19 370 23 207 218 4
Validation 68 68 61.2±10.3 0 100 1 3 2 58 4 40 27 1
PRAD Discovery 178 148 60.4±6.9 100 0 0 2 6 130 10 147 1 0
Validation 157 128 60.4±6.7 100 0 0 0 1 9 118 127 1 0
STAD Discovery 321 306 66.0±10.7 61.11 38.89 0 81 4 175 46 281 25 0
UCEC Discovery 248 248 63.1±11.1 0 100 10 13 25 193 7 231 17 0
Validation 280 247 64.7±11.3 0 100 3 6 52 167 19 221 26 0
TOTAL Discovery 4,034 3,827 59.9±13.2 39.29 60.71 15 183 225 3,125 279 2,719 1,102 5
Validation 1,627 1,388 59.7±13.1 44.09 55.91 5 35 150 983 215 1,116 270 2
AML, acute myeloid leukaemia; BRCA, breast adenocarcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; LGG, low grade
glioma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NA, not available; OV, ovarian carcinoma; PRAD, prostate adenocarcinoma; STAD, stomach adenocarcinoma; UCEC, uterine
corpus endometrial carcinoma.
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LGG having the highest and lowest mean ages, respectively
(Table 1). The sex distribution is generally consistent with US
general population cancer statistics for these malignancy types.
Age of onset distribution is bimodal for LGG, LUAD and STAD,
with some evidence of a bimodal distribution for OV, KIRC,
HNSC and GBM. Distinct age of onset populations may indicate
discrete mutational or disease processes (Fig. 1a).
Sequencing data for an additional 1,627 TCGA cases were
collected for 10 out of the 12 cancer types (AML and STAD not
included) for validating ﬁndings from the discovery cohort. In the
validation cohort, 1,388 TCGA cases had available demographic
information, of which 1,173 cases had ethnicity information,
where 83.8% were Caucasian (983 out of 1,173), 12.79% were
African American (150 out of 1,173), 2.98% were Asian (35 out of
1,173) and 0.4% (5 out of 1,173) were American Indian/Alaska
Native/Native Hawaiian or Other Paciﬁc Islander. Patients
(n¼ 1,388) were diagnosed between 19 and 90 years (mean
59.8±13.1 years), with LUAD and LGG having the highest and
lowest mean ages, respectively (Fig. 1a and Table 1).
Sequencing data for samples from the National Heart Lung and
Blood Institute (NHBLI) Women’s Health Initiative Exome
Sequencing Project (WHISP) were downloaded, processed and
used for comparison of genetic variants to TCGA cancer cases.
After extensive quality checks (see Methods), 1,039 Caucasians
with an average age of 63.7±7.9 years (mean±s.d., range 50–79)
were selected as controls for downstream burden test analyses
(Fig. 1b). NHLBI variant calls for 6,503 samples (4,300
Caucasians and 2,203 African American) were also downloaded
from the NHLBI Exome Variant Server (ESP6500SI-V2, http://
evs.gs.washington.edu/EVS/) for additional comparative analyses.
Landscape of germline truncation and missense variants.
Germline variant calling was conducted using VarScan10,
GATK11 and Pindel12 for TCGA discovery (4,034) and
validation (1,627) samples and Women’s Health Initiative
(WHI) (1,039) controls. False-positive ﬁlters were applied to the
intersected indel calls to ensure high quality for downstream
analyses. Missense variants were further analysed by comparing
with recurrent somatic mutation sites and IARC and ClinVar
databases (Supplementary Note 1). Examination of coverages in
the TCGA and WHI samples across the exome showed
comparable depths, with averages of 115.3 and 106.2,
respectively (see Supplementary Data 1). Speciﬁcally, there is a
high positive correlation (Pearson correlation R¼ 0.98) of the
percentage of coding regions with at least 30 coverage between
WHI (70.8%) and TCGA (71.4%) samples across the 624
cancer genes selected based on several recent studies13–17
(Supplementary Fig. 1).
We identiﬁed 2,089 truncation variants (splice site, frameshift
indels, nonstop and nonsense) in the TCGA discovery cohort in
624 cancer-associated genes (see Methods and Supplementary
Data 2–4). We limited our analysis to variants whose minor allele
frequency between our discovery data set and that of NHLBI
Exome Sequencing Project (ESP) 6,503 was r0.05%, based on
the distribution of minor allele frequencies across BRCA1 and
BRCA2 truncations detected (Supplementary Fig. 2). After
manual curation, we retained 838 truncation variants in 249
genes previously implicated in cancer (Supplementary Data 2);
69 of them with whole genome sequencing coverage have all been
conﬁrmed (Supplementary Data 4).
We conducted a more stringent investigation of the distribu-
tion of the rare truncation variants (MAFr0.05%) across cancer
types using two different gene sets: 114 well-known cancer
susceptibility genes reported by Rahman et al.1 and 47 DNA
repair genes associated with Fanconi Anaemia pathway3, with 15
overlapping between the two sets (Fig. 1c, and Supplementary
Data 5 and 6). Examination of the 114 susceptibility genes1
revealed that ovarian (19%, 95% conﬁdence interval (CI):
16–23%) and stomach (11%, 95% CI: 8–14%) cancers have the
highest percentage of cases carrying rare truncation variants,
while AML (4%, 95% CI: 2–8%) and GBM (4%, 95% CI: 3–8%)
have the lowest number of such events (Fig. 1c). Ovarian (17%,
95% CI: 14–20%), prostate (8%, 95% CI: 4–12%) and breast (8%,
95% CI: 6–10%) cancers exhibit the highest percentage of cases
harbouring rare truncations when the 47 DNA repair genes
associated with Fanconi Anaemia pathway are included. Stomach
cancer (8%, 95% CI: 5–11%) in the Fanconi Anaemia pathway-
related genes also displayed relatively high truncation rates.
Interestingly, LGG (2%, 95% CI: 1–5%) and KIRC (3%, 95% CI:
2–5%) have the lowest truncation rates in the Fanconi Anaemia
pathway-related genes, consistent with the small numbers of
somatic variants identiﬁed in these two cancer types.
Genes signiﬁcantly associated with cancer predisposition. Out
of 4,034 total discovery cases, 3,125 were identiﬁed as Caucasians
based on reported clinical data. We performed burden analysis in
Caucasians (3,125 cases versus 1039 WHI Caucasian controls, see
Supplementary Data 7) using well-established methods18,19 (see
Methods). To obtain the most comprehensive information, we
also performed comparisons between the TCGA 4,034 cases and
ESP 6,503 (downloaded variant calls, see Supplementary Data 8).
We searched for genes displaying signiﬁcantly higher rare
truncation variant frequencies than the background rate derived
from WHI 1,039 control set (see Methods) and identiﬁed 13
signiﬁcant genes (false discovery rate (FDR) r5%) using total
frequency test (TFT) calculations19, 5 from cross cancer-type
analysis and an additional 8 from individual cancer-type analysis,
with BRCA1, BRCA2, ATM, BRIP1 and PALB2 as the top 5
ranked genes associated in the Pan-Cancer analysis, and other
genes including CNKSR1, EME2, MRE11A, MSH6, PIK3C2G,
RAD51C, RAD51D and XRCC2 associated with speciﬁc cancer
types (Fig. 2a,b and Supplementary Data 7).
We detected 53 BRCA1 rare truncation variants across 7 cancer
types and 50 BRCA2 rare truncation variants across 6 cancer
types (Fig. 2c). As expected, most variants were detected in
ovarian and breast cancer cases. However, seven BRCA1 and six
BRCA2 germline truncations (MAFr0.05%) were detected in
other cancer types (three each in endometrial, stomach and lung
cancers, two in kidney cancer and one each in prostate and head
and neck cancers). The average age at diagnosis of BRCA1 and
BRCA2 germline truncation carriers versus non-carriers was non-
signiﬁcantly younger for endometrial (52.7 versus 63.1), stomach
(59.7 versus 66.1) and lung (63.0 versus 66.1) cancers, providing
support that these variants may contribute to younger onsets of
these cancer types, though additional data is required for
conﬁrmation and to reach statistical signiﬁcance. We also
observed 32 truncations in BRCA1 and BRCA2 interacting
proteins: PALB2 (n¼ 12, 4 in stomach, 3 in ovarian, 2 in head
and neck and each in breast, lung and prostate cancers), BRIP1
(n¼ 16, 3 each in breast, ovarian and lung, 2 in stomach, 1 each
in GBM, HNSC, KIRC, LGG and UCEC), and BAP1 (n¼ 2, in
kidney) and BARD1 (n¼ 2, 1 each in PRAD and BRCA). ATM
was the third most signiﬁcant gene and the third highest in
number of rare truncation variants; a total of 28 were found in
ATM (23) and its homologue, ATR (5) (Supplementary Data 7).
Our study bolsters evidence for previously claimed ATM/ATR
associations with breast cancer with observations of 4 ATM and 4
ATR truncations in breast cancer cases. Notably, 19 ATM
truncations were also detected in other cancer types, mostly in
lung, stomach and prostate cancers, the respective fractions of
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cases being 1.1% (5 out of 462 cases), 1.2% (4 out of 321 cases)
and 3.4% (6 out of 178 cases). These fractions are all higher than
the observed 0.5% in breast cancer. Both ATM and ATR are
serine/threonine protein kinases that act upstream from cell cycle
check point proteins CHEK2 (6) and CHEK1 (1), respectively.
The rest of the signiﬁcant genes were linked to various DNA
repair pathways. For example, MSH6 (11) is a component of the
mismatch repair pathway and XRCC2 (7), RAD51C (6), NBN (9)
are all part of the DNA double-strand repair pathway. ERCC1 (3)
and ERCC2 (10) are involved in transcription-coupled nucleotide
excision repair. Four rare truncations (two in LGG) were also
found in MUTYH (a mutY homologue), involved in oxidative
DNA damage repair (Supplementary Data 7).
We also sought to identify genes enriched for truncations that
were signiﬁcantly associated with single or a subset of cancer
types. RAD51C was found to be signiﬁcant in OV and signiﬁcant
and top ranked in AML, while PALB2 truncations were associated
with STAD and OV (Fig. 2b). PMS2, involved in colorectal20
and endometrial cancer21 predisposition, showed suggestive
associations with HNSC (TFT, FDR¼ 14%) and LGG (TFT,
FDR¼ 10%) in the discovery set, but did not reach the 5% FDR
threshold (Fig. 2b). Signiﬁcant enrichment of MSH6 (6 were close
to the C terminus of the protein) and MRE11A truncations were
found in UCEC. Other notable genes that were signiﬁcant in a
speciﬁc cancer type included EME1 in KIRC and FANCM in
BRCA (Fig. 2b and Supplementary Data 7). Notably, we observed
several novel associations between speciﬁc cancer types and
genes, including RAD51C in AML, ATM in PRAD, PALB2 and
EME2 in STAD.
To further evaluate these ﬁndings, we investigated rare
truncations in those 13 signiﬁcant genes, as well as an additional
21 suggestive genes having FDR r15% (TFT) using another
independent set of 1,627 cancer cases from 10 of the 12 cancer









































































































































































114 cancer susceptibility genes*47 genes associated with Fanconi Anemia Pathway
Figure 1 | Characteristics of the data. Data are distributed by age, cancer, cohort and carrier frequency. (a) Age of onset by cancer type. Average
age varies across cancer types, from 43 years in LGG to 67.7 years in LUSC. Note that LGG, LUAD and STAD show clear bimodal characteristics.
(b) Age distributions for discovery, validation and control cohorts. (c) Comparison of cancer gene truncation carrier frequencies across 12 cancer types.
The distribution of rare germline truncation variants for 12 cancer types (represented as the per cent of cases in each cancer type with rare germline
truncation mutation) in 2 different groups of cancer-associated genes (labelled on top of each bar plot): 114 cancer susceptibility genes from Rahman et al.1
and 47 genes associated with the DNA repair (Fanconi Anaemia) pathway3. There are 15 genes common to both groups. The total number of unique genes
from these 2 groups is 131.
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Figure 2 | Burden analysis reveals distinct set of cancer susceptibility genes across 12 cancer types. A total of 34 genes-of-interest were identiﬁed by
burden analysis by comparing the frequencies of rare truncation variants in Caucasian cancer cases (n¼ 3,125) versus their frequencies in the WHI control
population (n¼ 1,039). Two oncogenes (ABL2 and BCR) were omitted. (a) Signiﬁcant genes across Pan-Cancer types. Data were analysed with the total
frequency test (TFT) followed by false discovery rate (FDR) ranking. Dark horizontal line indicates the 5% FDR threshold, which is satisﬁed by ﬁve genes,
including BRCA1, BRCA2, ATM, BRIP1 and PALB2. Inset shows closer visual resolution. (b) Signiﬁcant genes for speciﬁc cancer types. Each plot shows the top
tested genes, by FDR, from the same TFTanalysis procedure for all 12 individual cancer types. Eight genes in addition to the ﬁve shown in a are signiﬁcant at
the 5% FDR level from cancer-type-speciﬁc analysis. (c) Cohort frequencies of genes. Bubble plot shows frequency of rare truncation mutation as a
percentage of cases in each cohort (all 4,034 cases included for frequency calculation). The x-axis denotes the test group of a speciﬁc cancer type, the
Pan-Cancer discovery cohort (4,034) and the validation cohort (1,627). Genes found to be signiﬁcant at 5% FDR using the Pan-Cancer discovery cohort are
labelled in boldface. Rings indicate genes that are signiﬁcant (TFT, FDR r5%) for a particular cohort on the x-axis. (d) Percentage of cases carrying rare
truncation in the 34 genes-of-interest across 12 cancer types in the discovery cohort.
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truncations (MAFr0.05%) were identiﬁed in 26 out of these
genes in the validation set (Supplementary Data 3). The overall
frequencies correlate positively (Pearson coefﬁcient of 0.6167,
Supplementary Fig. 3). Notably, 10 rare PMS2 truncations were
found in the validation set, with 4 from UCEC, 2 each from
LUAD and LUSC and 1 each from BRCA and PRAD; these
observations conﬁrm the signiﬁcance of PMS2 in susceptibility
and broaden its role in cancer types not previously implicated.
Another example is XPA detected as signiﬁcant using the
discovery cohort and conﬁrmed by the identiﬁcation of two
additional rare truncations (E111* and V244fs) in prostate cancer
using the validation cohort. Although three additional ATM rare
truncations were found in BRCA and GBM in the validation
cohort, no events were detected in LUAD and PRAD, two cancer
types with signiﬁcant results in the discovery cohort. Overall,
our results from the validation cohort strengthen provisional
conclusions derived in the discovery phase, but also indicate that
larger cohorts are required for accurately assessing frequencies of
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Cancer types OVAML BRCA GBM HNSC KIRC LGG LUAD LUSC UCECPRAD STAD
Figure 3 | Analysis of loss of heterozygosity in rare truncation and missense variants. (a) Bar plot shows individual truncations from nine genes (FDR
shown) with lengths representing ratios of tumour-to-normal variant allele fractions (that is, the fraction of reads containing the variant allele). Statistically
signiﬁcant events, deﬁned as FDRr5%, are shaded boldly, while non-signiﬁcant events are muted, with colours corresponding to genes. Cancer source of
each truncation is shown underneath, for example, most BRCA1 variants occur in ovarian and breast cancers and all BAP1 variants in KIRC. (b) Bar plot for
individual missense variants from four genes having elevated frequencies of such variants that show very signiﬁcant LOH, that is, at the 1% FDR level.
(c) Dot plot shows individual missense variants where abscissa and ordinate are amino acid positions and the ratio of tumour-to-normal variant allele
fraction, respectively. Blue and red indicate signiﬁcant (FDRr5%) and non-signiﬁcant events, respectively, with size of dots proportional to negative log of
the FDR. Annotated domains from the PFAM database are aligned with position, while shaded areas indicate ‘hotspot’ regions where variants having
signiﬁcant LOH cluster more than the rate explainable by chance. Plots are shown for ATM, BRCA1, BRCA2, FANCA and FANCM.
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LOH analysis of rare truncation and missense variants. While
burden analysis can identify genes with signiﬁcant enrichment of
rare truncations, association studies have limitations, speciﬁcally
with respect to inference about the functional implications of
speciﬁc variants. LOH analysis can uncover heterozygous germ-
line variants that are under potential selection in the tumour, one
of the key indications being increased VAF in the tumour sample.
With no LOH, it would be expected that the VAF detected in
tumour relative to the normal tissue-derived DNA would be 1,
while with complete LOH the VAF ratio would be 2. Because
tumour samples are not completely free of normal tissue and can
exhibit clonal heterogeneity, evidence for LOH is increasingly
strong for VAF ratios approaching 2. The combined use of
burden tests that can narrow the search space for germline
variants of functional importance with LOH analysis can solidify
support for both putative genes and speciﬁc variants involved in
cancer susceptibility.
With respect to genes, we ﬁrst tested the expanded list of
34 signiﬁcant or nearly signiﬁcant genes (known and likely
oncogenes excluded) in burden analysis (see Methods) for
evidence of somatic loss of the WT allele. A total of seven genes,
BRCA1, BRCA2, RAD51D, PALB2, RAD51C, ATM and BRIP1
were signiﬁcant (FDR r5%) along with two genes (BAP1 and
FANCM) near signiﬁcance (Supplementary Data 9 and 10, and
Figs 2 and 3a). Consistent with expectations, BRCA1 and BRCA2
had the highest percentage of signiﬁcant variants demonstrating
LOH (44 of 48 (92%) and 21 of 30 (70%), respectively). Other
genes demonstrating variants with LOH include: PALB2, which
functions in maintenance and repair and cooperates with BRCA2
(ref. 22) (5 signiﬁcant truncation mutations of 11, 45%); ATM,
which is activated by double-strand breaks (8 of 17 signiﬁcant,
47%); BAP1, a transcriptional repressor involved in BRCA1-
mediated cell growth suppression23 (2 of 2, 100%); and FANCM,
which plays a role in DNA repair24 (3 of 9, 33%). In all, 99 of 264
(38%) truncation variants showed signiﬁcant LOH. It is worth
noting that although LOH in cases with BRCA1 and BRCA2
truncations mutations were largely restricted to OV and BRCA,
the majority of LOH truncations in other genes (for example,
ATM, PALB2, BAP1, FANCM) were found across cancer types
(Fig. 3a).
We further compared VAFs of missense variants in the seven
signiﬁcant LOH genes above, ﬁnding that four in BRCA1, ATM,
BRCA2 and RAD51C are signiﬁcant. This underscores both our
ﬁndings from rare truncation analysis (Supplementary Data 11
and 12, and Fig. 3b) and the potential importance of missense
events in cancer. The signiﬁcant missense VAFs in these genes
range from 13 to 23% (Fig. 3b), while other genes average 9%.
Of all individual missense events, 173 of 1,170 (11%) showed
signiﬁcant LOH (FDR r1%) (Supplementary Data 12).
Signiﬁcant events for ATM and BRCA1 were concentrated in
BRCA, HNSC and OV, while RAD51C did not show preference
(Fig. 3b). Of note, our LOH analysis identiﬁed G245V in TP53 as
highly signiﬁcant (FDR¼ 1.18e-07) although no rare TP53
truncations were found.
To further investigate the effect of missense events on cancer
susceptibility, we sought to determine whether there are any
larger informative patterns associated with their LOH, speciﬁcally
whether the signiﬁcant instances of LOH spatially cluster in or
near speciﬁc protein regions/domains. Indeed, analysis shows
statistically signiﬁcant difference in spatial clustering, further
supporting the mechanistic roles of these variants in cancer
(Fig. 3c). For example, there is a strong grouping of variants
(FDR¼ 0.34%) that overlaps both a kinase-like and a PIK kinase
domain near the end of ATM, which participate in chromosome
maintenance and repair. We also found clusters overlapping the
BRCT (FDR¼ 5%) and RING domains (FDR¼ 0.39%), which
participate in the DNA repair functionality of BRCA1. Two
BRCA2 clusters (FDRs¼ 6.5% and 8.9%) in the oligonucleotide/
oligosaccharide binding motif (OB fold) domains, important in
the DNA damage response, are near signiﬁcant (Supplementary
Data 13).
Somatic and germline interactions and clinical associations.
We followed stringent ﬁltering strategies13 for standardizing
speciﬁcity across the Pan-Cancer somatic variant calls for 3,368











































































































































Genes with recurrent somatic mutations






















































































































































Figure 4 | Molecular interactions between rare germline variants and somatic mutations within and across cancer types. (a) Heatmap demonstrates
the signiﬁcance of interactions between 34 burden test signiﬁcant genes and 54 cancer-associated genes (top 30 are shown) with recurrently mutated
somatic variants across cancer types. Red–white colour scale and blue–white colour scale depict the negative log of P-value for mutual exclusivity and
co-occurrence, respectively. Both are based on the MuSiC permutation test (n¼ 10,000). (b) Abacus plot displays the distribution of signiﬁcant, mutually
exclusive rare germline variants and somatic mutations across all 12 cancer types. Unique combinations of germline and somatic variants contribute
to the development of individual cancer types. Bigger dots indicate recurrent genes across cancer types, while smaller dots indicate cancer-type-enriched
genes.
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MuSiC25 to search for genes demonstrating co-occurring or
mutually exclusive germline and somatic mutations (Fig. 4a,b
and Supplementary Data 15 and 16). Our Pan-Cancer analysis
using 34 burden test genes-of-interest and 54 cancer-associated
genes with recurrently mutated somatic variants (frequency Z5
across cancer types) detected signiﬁcant mutual exclusivity between
BRCA1/BRCA2 germline truncations and IDH1 somatic mutations,
which is likely confounded by cancer-type speciﬁcity: BRCA1/
BRCA2 germline truncations were most prevalent in BRCA and
OV, whereas IDH1 somatic variants are mostly found in AML,
GBM and BLCA. To mitigate the cancer-type-speciﬁc effect, we
investigated co-occurrence and mutual exclusivity within each
cancer type (requiring recurrently mutated somatic variants with
frequency Z2 across cancer types) (Supplementary Data 16).
Notably, ATM germline truncations were found to be mutually
exclusive of TP53 somatic mutations in LUAD (permutation test,
P¼ 0.041), consistent with the paradigm that ATM activates TP53
to trigger apoptosis26 and the need to disrupt only one gene to
confer an anti-apoptotic effect. As expected, we also observed
co-occurrence of BRCA1 germline truncations and TP53 somatic
mutations in BRCA (permutation test, P¼ 0.012)27, as well as
mutual exclusivity between BRCA1/BRCA2 germline truncations
and PIK3CA somatic mutations in BRCA (permutation test,
P¼ 0.01 and P¼ 0.03). BRCA1 germline truncations have
previously been reported to be associated with the basal subtype
breast cancer28, which tends to exhibit a molecular proﬁle similar
to ovarian cancer29. Our ﬁndings are consistent with the
association between basal subtype breast cancer and frequent
TP53 and infrequent PIK3CA mutations30. In addition, we also
observed a co-occurrence of BRCA2 germline truncations and TP53
somatic mutations in ovarian cancer, as expected. Our data suggest
that the combinational effects of BRCA1/BRCA2 germline
mutations, along with the high frequency of LOH events and
somatic TP53 mutations result in aggressive basal subtype breast
cancer and ovarian cancer.
Interestingly, the distribution of BRCA1, BRCA2 and ATM rare
germline truncations with their somatic mutations across cancer
types varies with the high frequency of ATM in prostate, lung and
stomach cancers, and BRCA1 and BRCA2 germline events in
ovarian and breast cancers (Fig. 5a and Supplementary Data 17).
Collectively, these analyses show distinct combinations of
germline and somatic mutations contribute to the development
of individual cancer types.
We also examined germline variants having signiﬁcant impact
on carriers’ somatic mutation frequencies. Analysis of the
expanded 34 burden test genes revealed that patients with
germline BRCA1 and BRCA2 truncations had signiﬁcantly higher
somatic mutation frequencies than cases without such changes in
both breast and ovarian cancers (Fig. 5b and Supplementary Data
18). Since the correlation between BRCA1/2 germline and higher
somatic mutation rate may be characteristic of the basal subtype
breast cancer, we compared the mutation frequency of basal cases
with BRCA1/2 germline truncation to basal cases without BRCA1/
2 germline truncation and found the former have signiﬁcantly
higher mutation rate (Supplementary Fig. 4, Wilcoxon rank-sum
test, P¼ 9e-4).
In addition, RAD51C and RAD51D germline truncations are
positively correlated with increased somatic mutation frequencies
in ovarian cancer. FANCM and EME1 germline truncations
are positively correlated with increased somatic mutation
frequencies in HNSC (Wilcoxon rank-sum test, P¼ 0.046) and
KIRC (Wilcoxon rank-sum test, P¼ 0.027), respectively.
In UCEC, MSH6 germline truncations are found to be
signiﬁcantly associated with higher mutation frequencies, as
expected (Wilcoxon rank-sum test, P¼ 0.014) (Fig. 5b and
Supplementary Data 18). Further, 81 cases carried MSH2
germline variants (MAFr0.05%, including 1 truncation variant),
and they also showed higher somatic mutation frequency
(Wilcoxon rank-sum test, P¼ 3.63e-03).
The joint analysis of all 12 cancer types including cancer
type as a covariate identiﬁed BRCA1, BRCA2 and PMS2 as having
strong correlations with a younger age of onset (P¼ 5.20e-07,
2.04e-04 and 0.049, respectively; MuSiC GLM analysis, Fig. 5c
and Supplementary Data 19). Analysis of individual cancer types
revealed signiﬁcant early onset for germline truncations of
FANCA in HNSC, BRIP1 in LUSC and ATM in STAD (Fig. 5c
and Supplementary Data 20). Not surprisingly, we found that
germline truncation variants in 47 Fanconi Anaemia genes
and 114 cancer susceptibility reported in Rahman et al.1 were
signiﬁcantly enriched in younger patients according to Wilcoxon
rank-sum testing (P¼ 1.08e-03 and 1.38e-04, respectively).
Functional validation of BRCA1 missense variants. To investi-
gate the effect of missense variants on BRCA1 function and
evaluate LOH analysis for missense variants, 68 variants were
selected based on MAF and protein domains for functional
validation using the HDR assay31 (see Methods and
Supplementary Data 21); 47 of them had previously been
assigned as variants of unknown clinical importance in the
NHGRI BIC database and 15 variants were not reported at all in
BIC. One known deleterious truncation mutation in the carboxyl
terminus of the BRCA1 protein Q1779fs and three other
truncations—E1250*, E1415fs and E23fs—discovered in UCEC
were also included in the experiment. We successfully introduced
68 missense variants and 4 truncation variants into full-length
BRCA1 expression plasmid pcDNA-50HA-BRCA1 for the in vitro
HDR assay as previously described31,32 (Supplementary Data 21).
All mutant constructs were conﬁrmed by sequencing and protein
expression (Supplementary Fig. 5) and tested in triplicate using
the in vitro assay. The percentages of cells showing green
ﬂuorescent protein (GFP) expression were normalized to
homologous recombination levels observed in cells depleted of
endogenous BRCA1 and rescued by transfection of the WT
BRCA1 expression vector (see Methods).
Among all tested variants, all four truncations (three from
UCEC) and six missense variants retained less than 30% of
homologous recombination activities relative to WT BRCA1,
and are therefore considered HDR-defective (Supplementary
Data 22). These missense variants included C61G (observed in
four cases), C64G (two cases), T1685I (one case), R1699W (two
cases), L1786P (one case) and G1788V (one case); all of them
showed signiﬁcant enrichments in the tumour samples based on
LOH analysis (Fig. 6a). Comparative analysis of RNA-seq data
from two carriers and four non-carriers suggests C64G is in fact a
variant affecting splicing (Supplementary Fig. 6), consistent with
a previous report33, and our results suggest that should some of
the C64G mRNAs be properly spliced the protein is not active in
DNA repair. Of particular interest, L1786P, identiﬁed and
validated as HDR-defective in our study, has not been
previously designated as pathogenic, despite observations in two
previous studies34,35. Our analysis of the crystal structure of the
BRCT domain showed that the substitution of leucine with
proline in L1786P will likely result in the termination of the alpha
helix structure, which may cause the loss of BRCA1 HDR
function. Interestingly, additional three variants, A1708V,
M1783T and R1835Q (from one patient each) consistently
displayed less than 70% HDR function in comparison to WT
BRCA1 (partial HDR-defective, Fig. 6a); all three had previously
been designated as variants of unknown signiﬁcance in the BIC
database. It is worth noting that A1708V and R1835Q were found
in male patients with kidney and stomach cancers, respectively;
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both developed cancers at age of 48. A1708V has previously been
characterized as a low-to-moderate risk variant36 and R1835Q
has been identiﬁed in a Malay population of early-onset breast
cancer patients with a personal or family breast cancer history37.
One endometrial cancer patient harbouring M1783T was
diagnosed at age of 65. The BRCA1 protein harbouring this
variant was previously shown to possess enhanced protease
sensitivity38. Further, our analysis shows that all seven HDR-
defective or partial defective missense variants from the
BRCT domain are either positioned in the centre of the
structure or on the surface responsible for protein–protein
interactions, while the 5 HDR-WT variants from the BRCT
domain tested are mapped to the periphery of the structure
(Fig. 6b). In addition, these nine HDR-defective (or partial
HDR defective) missense variants are mutually exclusive to
BRCA1 somatic mutations and germline truncation variants
(Supplementary Data 2 and 14).
Using the systematic BRCA1 missense variant validation data,
we evaluated the prediction power of LOH analysis for identifying
candidate variants of functional relevance. Without LOH analysis
ﬁltering, we observed a rate of 4.7% (3 of 64 validated), but
BRCA1 validation of candidates ﬁltered through LOH was
increased to 38.1% (8 of 21) (Supplementary Data 23). The
signiﬁcant difference (P value¼ 0.0004, Fisher’s test) suggests
LOH offers an effective sieve for candidates, which in this case
gives an estimated enrichment factor of eightfold.
Discussion
This study of over 4,000 cancer cases is the largest integrated
analysis of germline and somatic variants to date. Our systematic
analysis indicated that an estimated 18% of cancer cases from the
TCGA cohort had Z1 rare truncations in 624 genes associated
with cancer. Further, there was signiﬁcant enrichment of rare
truncation variants in 13 genes and suggestive evidence of
increases in 21 more, comprising 8.3% (333 out of 4,034) of
TCGA cancer cases.
We observed several signiﬁcant associations in speciﬁc cancer
types: RAD51C in AML, ATM in PRAD and PALB2 in STAD.
Across cancer types, a higher percentage of breast and ovarian
cancer cases were identiﬁed as having rare truncation variants in
cancer genes versus other cancer types, due predominantly to
high frequencies in BRCA1/2. The percentage of breast and
ovarian cancer cases carrying BRCA1/2 germline truncation
variants in the TCGA cohort was 4.4% and 11.6%, respectively,
consistent with previous reports39–42. Interestingly, stomach
cancer has the second highest percentage of rare truncations in
114 genes previously reported1, largely due to the contributions
from ATM, BRIP1, PALB2, XRCC2 and others. In contrast, for
KIRC and GBM, truncation variants in the 34 associated germline
genes were uncommon, identiﬁed in only less than 6% of cases
(Fig. 2d). These results contribute to our understanding of the
genetic architecture of cancers, complementing the known effect
of common and tagged variants from array-based studies43, as
well as the estimate of overall heritability from twin studies in
multiple cancer types44.
Our results indicated that germline truncation and missense
variants in several genes were under selection in the tumour, with
ATM, BRCA1, BRCA2 and RAD51C determined as signiﬁcant
from both truncation and missense analyses and BAP1, BRIP1,
FANCM, PALB2 and RAD51D from truncation analysis alone. As
a proof-of-concept, we performed functional validation for 68


































































































































































































Figure 5 | Germline variants correlate with somatic mutations and age at diagnosis. (a) Barplot illustrates the distribution of BRCA1, BRCA2 and ATM
somatic and germline mutations across cancer types. (b,c) Panels display genes signiﬁcantly correlated with somatic mutation frequency and younger age
of onset in different cancer types and in Pan-Cancer. The width of the shape indicates the density, and the horizontal line indicates the median. P value is
calculated by the Wilcoxon rank-sum test and is indicated by the size of the uppermost circles.
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efforts identiﬁed 9 variants from 14 patients with complete or
partial defective HDR function and validated our LOH analysis
for effective enrichment of variants under functional selection
(an estimated eightfold enrichment in BRCA1).
More importantly, our integrated germline and somatic study
identiﬁed BRCA1, BRCA2, RAD51C, RAD51D, FANCM, EME1
and MSH6 germline truncations signiﬁcantly associated with
increased somatic mutation frequencies in speciﬁc cancer types,
suggesting that germline defects in DNA repair expand to the
somatic level. Further, our search for co-occurring or mutually
exclusive germline truncation/somatic mutations across 12 cancer
types revealed a number of important insights in terms of genes
and pathways involved including: (1) the association between
germline BRCA1/2 germline truncations and frequent TP53 and
infrequent PIK3CA somatic mutations conﬁrm breast cancer
clinical subtype classiﬁcation; and (2) ATM as a bona ﬁde (third
frequently truncated) susceptibility gene demonstrated by both
burden and LOH analyses is the only common gene highly
mutated at both germline and somatic levels.
Although our study has been revealing at a genetic level, we are
mindful of the limitations of the TCGA data set, including the
lack of detailed family history information that would further
inform the potential pathogenicity of germline variants. Despite
the large sample size overall, our inferences are limited for speciﬁc
cancer types because of small case numbers. In addition, the vast
majority of TCGA cases in our sample set were of European
background, emphasizing the need for the development of a

































































































































































































































































































Figure 6 | Functional validation of BRCA1 missense and truncation variants. (a) 68 rare missense and 4 truncation variant sites were tested by HDR
assay. All samples were depleted of endogenous BRCA1 by transfection of a siRNA targeting the 30-untranslated region. Indicated in the legend are the
plasmids transfected to test for rescue of BRCA1 activity. ‘pcDNA3’ is empty vector and ‘WT’ represents wild-type BRCA1 plasmid. The y-axis denotes the
HDR activity relative to the wild-type BRCA1 protein. Error bars depict s.d. from the mean. Dots on the x-axis represent LOH status, each dot corresponding
to one case. Blue, red, dark grey and light grey denote statistical signiﬁcance, non-signiﬁcance, unknown LOH (due to lack of sufﬁcient coverage) and
untested, respectively. Variants in different functional domains are indicated with colours as follows: orange, RING domain; green, nuclear localization signal
(NLS); blue, DNA-binding region; purple, a SQ/TQ cluster domain (SCD); and red, BRCA1 C-terminal domain (BRCT). All the HDR assays were tested in
triplicate. (b) Crystal structure of the BRCA1 RING (left) domain in complex with the BARD1 RING domain (labelled in grey) and BRCTdomain (right panel)
are displayed, with HDR-defective variants labelled in red and partial HDR-defective variants tagged in orange. Variants in yellow are functional in the HDR
assay.
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predisposition variants from ancestrally diverse population
groups. Nonetheless, this study is the largest to date that has
integrated somatic and germline alterations to identify important
genes across 12 major types contributing to cancer susceptibility
and our results provide a promising list of candidate genes for
deﬁnitive association and functional analyses. The combination of
high throughput discovery and experimental validation should
identify the most functionally and clinically relevant variants for
cancer risk assessment.
Methods
Access and inclusion. Approval for access to TCGA case sequence and clinical data
was obtained from the database of Genotypes and Phenotypes (dbGaP) (document
#3281 Discover germline cancer predisposition variants). We selected a total of 4,034
discovery cases and 1,627 validation cases with germline and tumour DNA sequenced
by exome capture followed by next-generation sequencing on Illumina or SOLiD
platforms. All cases met our inclusion criteria of 50% coverage of the targeted exome
having at least 20 coverage in both germline and tumour samples.
Control cohort. NHLBI variant calls for 6,503 samples (2,203 African-Americans
and 4,300 European-Americans unrelated individuals) were downloaded from the
NHLBI GO ESP, Seattle, WA (http://evs.gs.washington.edu/EVS/; accessed on
26 August 2013). For comparative analysis, all ESP variants were ﬁltered for
o0.1% total MAF to minimize false-positives. For the WHISP sample set
(N¼ 1039) as part of the NHLBI ESP cohort, we performed variant analyses using
methods described in the following section. All variants were processed using the
same tools as for the TCGA cohort. dbGaP accession ID for NHLBI ESP is
phs00281.
Germline variant calling and ﬁltering. Sequence data from paired tumour and
germline samples were aligned independently to GRCh37-lite version of the human
reference using BWA v0.5.9 and de-duplicated using Picard 1.29. Germline SNPs
were identiﬁed using Varscan (version 2.2.6 with default parameters except –min-
var-freq 0.10--P value 0.1--min-coverage 8–map-quality 10) and GATK (revi-
sion5336) in single-sample mode for normal and tumour BAMs. For breast and
endometrial cancer samples, we also used population-based methods, but found
differences to be minimal. Germline indels were identiﬁed using Varscan 2.2.9
(with default parameters except --min-coverage 3–min-var-freq 0.2–P-value 0.10–
strand-ﬁlter 1–map-quality 10) and GATK (revision5336, only for AML, BRCA,
OV and UCEC) in a single-sample mode. We also applied Pindel (version 0.2.4 ,
8 May 2013; window-size 1) on each pair of tumour and germline sequencing data
(for some samples, multiple normal ﬁles are used if available) for indel prediction.
For the analysis, we preset the insertion size to be 500 if this information was not
provided in the BAM header.
For each cancer type, all variants were limited to coding regions of full length
transcripts obtained from Ensembl release 70. In addition to the coding regions, the
two base pairs ﬂanking each exon that cover splice donor/acceptor sites were
included and annotated with reference to the distance to the nearest coding exon
(e). Single nucleotide variants (SNVs) were based on the union of GATK and
VarScan. They were subsequently processed through our in-house false-positive
ﬁlter (with default parameters except--min-homopolymer 10). We required that
indels were called by at least two out of three callers (GATK, Varscan, Pindel) when
all three callers were applied. In addition we also included Pindel unique calls (at
least 30 coverage and 20% VAF). All combined indels were then processed
through our false-positive ﬁlter (with default parameters except--min-
homopolymer 10 –min-var-freq 0.2 --min-var-count¼ 6). We then applied
additional annotation and minor allele frequency ﬁlters as previously reported3.
The predictions for 4,034 TCGA cases consist of 2,709,906 variants (1,655,391
missense, 947,045 silent, 36,009 nonsense, 18,693 splice site, 2,041 nonstop/
readthrough, 30,508 frameshift indels and 20,219 in-frame indels) with minor allele
frequencyr1% in 1000 Genomes, ESP 6,503 data set, Discovery 4,034 cohort and
additional annotation ﬁlters as previously reported3; of these, 1,842,459 variants
were from 3,125 Caucasian TCGA cases. Using the same processing for the 1,039
WHI Caucasian controls, we identiﬁed 516,219 variants, consisting of 319,698
missense, 176,862 silent, 6,274 nonsense, 3,541 splice site, 355 nonstop/
readthrough, 6,101 frameshift indels and 3,568 in-frame indels.
Cancer-associated genes. A total of 624 candidate cancer-associated genes were
compiled from 9 sources, including recently published large-scale cancer studies,
publicly available screening panels and unpublished preliminary analysis of pub-
licly available data sources. We retained 204 genes shared across at least 2 of the 9
sources and a literature search was conducted to identify evidence supporting
inclusion of any remaining unique genes. A subset of 518 genes originated from
recent publications, including 294 genes from Frampton et al.17, 125 from Kandoth
et al.13, 212 from Lawrence et al.15, 194 from Pritchard et al.16, 114 from Rahman
et al.1 and 124 from Vogelstein et al.14 Thirty-nine additional genes were included
based on the analysis of driver mutations in publicly available TCGA data, the
published guidelines for return of results of the American College of Genetics
and Genomics45 and 18 novel cancer driver genes identiﬁed in recently published
large-scale studies.
Germline sites overlapping with recurrent somatic mutations. Recurrent
somatic mutations were extracted from the high conﬁdence ﬁltered set of somatic
mutations13 and germline variants overlapping them were further ﬁltered to
remove those having a reported global MAF40.5% in the NHLBI Exomes
(ESP6500SI-V2). Remaining variants were ﬁltered to remove artifacts due to
ambiguous alignments, simple repeats, reference sequence errors, putative somatic
mutations in adjacent normal tissue, somatic mutations associated with clonal
expansion in blood46 and variants with a VAFo10% in tumour or normal.
No germline mutations were found to overlap somatic mutations in the same
individual.
In addition to sites described in the main text, several rare germline variants
overlapping somatic mutations in genes associated with toxin metabolism were also
identiﬁed. This included three cases carrying CYP2D6 (H352R), as well as
one carrier of ABCC2 (E943K; rs3740065). Variants in both genes have been
reported to be associated with poor outcome in post-menopausal women treated
with tamoxifen47,48 but their association with cancer predisposition remains
undetermined. In addition, a germline variant at somatic R423Q site was found in
the CARD11 oncogene49 and another germline variant S650L in PDGFRB was
identiﬁed. Interestingly, a FLT3 germline variant (R387Q) was identiﬁed to have an
overlapping somatic mutation in endometrial cancer.
Identifying signiﬁcant genes using burden tests. We determined the MAF
cutoff for rare variants as 0.05% based on balancing the inclusion of possible
false-positives versus the loss of possible true-positives in subsequent burden test
and LOH analysis. For example, if one presumes that P values p0.01 have a
reasonable possibility of being retained as signiﬁcant in a multiple hypothesis test,
the 0.05 threshold only excludes 2 such points out of a total of 47 for BRCA1 and
1 such point out of a total of 52 for BRCA2. Conversely, it excludes 24 points in the
MAF range up to 1% that are very unlikely to show signiﬁcance. Points having
MAF41% are likewise not likely to be of interest (Supplementary Fig. 2).
Burden test analysis was performed by comparing the frequency of rare
germline truncation mutations in cancer-associated genes from the Pan-Cancer
12 germline data set (from 12 cancer types; cohort size¼ 4,034) with WHI 1,039
control samples and those downloaded from the NHLBI ESP (6,503 including
2,203 African-Americans and 4,300 European-Americans unrelated individuals).
Variant calling on the TCGA and WHI data set was done as previously described
in the Methods section. Variants for the ESP 6,503, along with their minor allele
frequency were downloaded from http://evs.gs.washington.edu/EVS/). The
truncation variants (nonsense, splice_site, and frameshift indels) from both groups
were limited to a list of genes previously associated with cancer (see cancer-
associated genes section). Further ﬁltering includes retaining variants with o1%
minor allele frequency from 1000 Genomes Project and o1% cohort frequency in
each cancer type. A pooled minor allele frequency (the average minor allele
frequency of each variant between the test and control group) was calculated for
each variant and only those whose pooled minor allele frequency waso0.05% were
kept for burden analysis. We excluded events having insufﬁcient numbers of
observations, deﬁned here as fewer than three in the combined cases and controls
for the ESP cohort and fewer than two in the WHI cohort. We subjected the data to
the TFT, evaluating the one-tailed P value in each case (observations signiﬁcantly
greater than controls). For reference, we also evaluated the data using the cohort
allelic sum test, although these results were not carried forward for analysis,
because they correlate with TFT. The TFT probabilities were then ranked by the
standard FDR. This procedure was performed for each cancer type versus the
control group. In addition, an overall burden test was performed for Pan-Cancer
12 germline data set versus the control group. A FDR cutoff of 10% for the
Pan-Cancer 12 germline data set was used.
Statistical methods of LOH analysis. Next-generation sequencing provides direct
read counts of reference and variant alleles and each pair of counts comprises
an observational sample of the actual variant allele fraction (VAFs) at its site.
We devised several statistical procedures using these counts to test for allelic
enrichment at sites within a subset of genes hypothesized to be relevant across
cancer types and, moreover, to test the genes themselves for signiﬁcant content of
such sites. This is one component of a larger method to assess loss-of-function
alleles in these genes.
The evaluation at each tumour variant site (truncation or missense) is based on
two complementary aspects related to its VAF: (1) whether it is signiﬁcantly higher
than the VAF at its corresponding site in the matched normal sample and
(2) whether it is signiﬁcantly higher than the characteristic VAF in the general
population of genes having somatic mutations. The ﬁrst aspect was implemented
using Fisher’s exact test50 on a 2 2 table of allele type (reference and variant)
versus sample type (tumour and normal). For the second test, we permuted all
combinations of reference counts and variant counts of the somatic events for all
other genes, thus obtaining a null distribution that can be used for computing tailed
P values.
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Each of these two calculations uses some component of unique information not
available to the other: they are essentially independent tests of the same hypothesis.
We used a standard transformation method from the mathematical statistics
literature to combine these values into a single, overall result51. The list of P values
for the entire complement of tested sites was then corrected for multiple hypothesis
testing bias and ranked using the standard Benjamini–Hochberg FDR
calculation52.
For the second type of test at the gene level, we took the following approach for
truncation events. All mutated sites for the candidate gene were catalogued, as were
all sites outside of that gene, the latter representing the mutation ‘background’. The
statistical difference between the two sets was then calculated using a standard
difference-of-means t-test on the tumour VAFs of the two groups, where the
number of degrees of freedom is 2 less than the total number of sites in the test.
This procedure was repeated for each gene-of-interest, after which multiple testing
correction was again applied in the context of FDR. With respect to missense
events, we found this procedure was not sufﬁciently sensitive, so we used an
alternative test based on comparing the fraction of missense sites within each gene
that showed signiﬁcant LOH on the individual level to the corresponding fraction
in a background set consisting of the genes from burden testing that did not show
signiﬁcant LOH for truncations. To minimize noise, we adopted somewhat strict
criteria for this particular test: to be tallied as LOH, a site must have had a
maximum of 1% FDR in the site test and we only tested genes that satisﬁed the
following inclusion criteria: a minimum difference of fractional values of two
percentage points and at least three events showing LOH at the 1% FDR
level. We then applied Fisher’s exact test on 2 2 tables of missense type
(signiﬁcant LOH and no discernable imbalance) versus cohort (test gene
and background population), after which FDR was once again applied to the
result.
An important aspect of the above methods is pre-conditioning of inputs.
Previous studies53 have discarded sites based on their inability to attain a
signiﬁcant P value under the test being used, pointing out incidentally that
excluding sites directly improves FDR. The latter observation is undoubtedly true,
but this view misses the importance of the conﬁdence level associated with a VAF
estimate, as determined by the size of the sample used for its computation. Because
of depth variations both between samples and within samples, the reliability
(conﬁdence) of VAF estimates as calculated from read counts varies from site to
site. A speciﬁed CI for each VAF furnish is a rigorous metric on which reliability
can be assessed and low-reliability points subsequently excluded from analysis.
Because VAFs can approach the extremes of 0 and 1 and are also sometimes based
on only 10 or 15 reads, the standard interval from sampling theory is not
particularly useful. Instead, we used Wilson’s interval54, which does not suffer
appreciably in these circumstances. We chose an interval of 90% conﬁdence
(Z-score of B1.65), removing events whose larger distance (above or below the
calculated VAF) exceeded 12%. The remaining ‘high-quality’ data were then used
in the tests described above. Results having FDR r20% were prioritized as
signiﬁcant.
LOH analysis of germline truncations and missense variants. We applied our
LOH analysis method as a reﬁnement step to the burden analysis. Speciﬁcally,
we tested all sites (and by extension the genes containing those sites) that burden
testing identiﬁed as being signiﬁcant, either in a Pan-Cancer context or as
associated with a speciﬁc cancer type. Here we used a FDR of 15% to capture
the widest set of genes that could be signiﬁcant. In a sense, we used our LOH
method as a ‘conﬁdence ﬁlter’ situated on top of burden analysis to eliminate
false-positives. With oncogenes removed, the list of candidates at this stage
consisted of 32 genes, including ATM, BRCA1, BRCA2, BRIP1, MSH6 and RAD51C
(the ‘burden test genes’). We also separated missense from nonsense alterations,
the latter typically resulting in truncated, non-functional protein products and
analysed these sets separately.
The statistical procedure outlined above is straightforward, but can be applied
in various ways. For assessing the burden test genes, we selected each one
individually and constructed the corresponding null distribution from all
remaining non-burden test genes. That is, we excluded from the null all those genes
for which there was already some evidence of possible signiﬁcance. The same
principle applied to testing individual sites: no variants from burden test genes
were included in the null distributions.
Calculation of hotspots of signiﬁcant LOH. The calculation method for LOH
discussed above identiﬁes instances where the observed VAF in the tumour is
higher than what is attributable to chance. Building on this, we now describe a
subsequent calculation that identiﬁes groups of such instances that are clustered
spatially. These groupings are so-called ‘hotspots of signiﬁcant LOH’ and signal
likely biological relevance. The null hypothesis is that instances of LOH, whether
statistically signiﬁcant or not, are distributed randomly. Since we are primarily
interested in discovery, test regions are implemented as unbiased ‘sliding windows’
rather than as speciﬁc domains, linkers and so on. A relevant LOH observation
must satisfy two conditions:
 condition A: the LOH is statistically signiﬁcant, as described above
 condition B: the LOH resides within the current test window
Status and spatial placement are independent of one another, meaning that the
Bernoulli probability of a single LOH observation can be calculated as
pb ¼ P A\Bð Þ ¼ Ds WDs þDnð Þ  L ð1Þ
where W and L are the sizes of the test window and protein, respectively
(in units of amino acids) and Ds and Dn are the total numbers of signiﬁcant
and non-signiﬁcant LOHs observed for the protein. This expression indicates
observations are of greater weight to the degree that the signiﬁcant LOHs are more
rare (as compared to non-signiﬁcant LOHs) in the test set and that they cluster
within tighter regions. LOHs are independently and identically distributed under
the null hypothesis, meaning the mass probability of k observations of signiﬁcant
LOH within the window is then
P kð Þ ¼ Ds þDn
k
 
 pkb  1 pbð ÞDs þDn  k ð2Þ
and the signiﬁcance (test) probability of k observations within a test window is
PS ¼ P kð ÞþP kþ 1ð Þþ    þP Ds þDnð Þ ð3Þ
Since pb is constant over a given protein for a given window size, appreciable
caching can be used to economize the calculation. We use a slide-step of 1 amino
acid and scan window sizes from 30 to 200, taking regions of signiﬁcance to be
characterized by their smallest PS. The software automatically merges overlapping
signiﬁcant regions. Standard FDR analysis, as described above, is then performed
on the resulting list of hotspots.
Functional validation of BRCA1 variants. Variants were incorporated into a full-
length BRCA1 expression plasmid, pcDNA-50HA-BRCA1, using Q5 site-directed
mutagenesis kit (New England BioLabs). Primer sequences are available in
Supplementary Data 21. All of the desired variants were conﬁrmed by sequencing.
HeLa-DR cells, a stable derivative of HeLa cells containing the genomic
integration of the recombination substrate vector, pDR–GFP were used for the
homology-directed recombination assay. Co-transfection of HeLa-DR cells with
the BRCA1 expression plasmid containing the test variant and siRNA targeting the
30-untranslated region of the BRCA1 gene to deplete endogenous BRCA1
expression was performed. Two days later, cells were transfected again with the
siRNA, BRCA1 expression plasmid and the I-SceI expression plasmid. After 3 days,
cells were harvested by trypsinization and the fraction of GFP-positive cells was
determined using a FACScalibur ﬂow cytometer (BD Biosciences model E1202).
The plasmids and cell line used in this study have been described previously31.
All BRCA1 variants were tested in triplicate and the percentage of cells with
GFP expression was normalized to the rescue by wild-type BRCA1 expression
plasmid.
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